The latter is based on encouraging pre-clinical results in orthotopic glioma mouse models revealing that D2C7-IT plus anti-CD40 agonist treatment elicited an anti-tumoral phenotype of macrophages and microglia and drove an effective CD8+ T cell response (91). This evidence concerns the gene CD40 and central nervous system cancer.